Search results

1

Irrigated DiamondTemp catheter and return to ablation under temperature control. First Polish experience with DiamondTemp catheter in pulmonary vein isolation

100%

Koźluk E., Piątkowska A., Rodkiewicz D., Opolski G.

European Journal of Translational and Clinical Medicine

|

2021

|

vol. 4

|

issue 2

44-51

EN

We present the first Polish experience with ablation performed using DiamondTemp catheter. The study was conducted with 3 male patients diagnosed with atrial fibrillation (AF). In the first 2 patients typical transseptal punctures were performed, followed by mapping with the Advisor catheter and EnSite-Precision system. One patient had a residual atrial septal leak, therefore ablation without fluoroscopy was attempted. High-power, short-duration ablation under temperature control was performed around pulmonary vein (PV) ostia. The power was 49-53 W, the temperature was 45-48 ͦC. Duration of procedures/fluoroscopy were: 146/8.9, 177/5.9, 132/0.0 min. In the reference group, 10 recent AF identical ablation procedures performed with traditional equipment resulted in 143.0±27.0/6.0±4.4 min. Duration of DiamondTemp applications were 14.7, 32.7, 30.8 min (reference group 37.3 ± 11.4 min). Procedural endpoints were achieved in all but one patient with incomplete isolation of the low segment of the right inferior PV. There were no procedural complications noted. In conclusion, the DiamondTemp saline-irrigated catheter is safe and effective for high-power short-duration ablation in patients with AF. Furthermore, this technology makes it possible to complete the procedure without fluoroscopy. However these findings must be confirmed in larger group of patients.

2

Stanowisko w sprawie stosowania niepegylowanej liposomalnej doksorubicyny u chorych na chłoniaki ze współistniejącymi chorobami sercowo-naczyniowymi

100%

Szmit S., Jędrzejczak W. W., Opolski G.

OncoReview

|

2013

|

vol. 3

|

issue 3

213-215

3

Cardioneuroablation in neurocardiogenic syncope – hype or hope?

100%

Koźluk E., Piątkowska A., Rodkiewicz D., Opolski G.

European Journal of Translational and Clinical Medicine

|

2022

|

vol. 5

|

issue 1

47-52

EN

We are presenting the ablation of parasympathetic ganglia in the atria as a new method of treatment of vasovagal and other neurocardiogenic syncope. This method, shifting the balance of the autonomic nervous system in the sympathetic direction, is directed to the immediate cause of syncope which is excessive activation of the vagus nerve. Its effectiveness in the annual observation is within 80-100%. This method offers a great chance to improve the quality of life in patients with reflex syncope what have not been prevented by conventional treatment.

4

High-power and short-duration ablation with the Qdot+ algorithm for pulmonary vein isolation and the right superior ganglion plexus ablation without fluoroscopy

100%

Koźluk E., Piątkowska A., Rodkiewicz D., Opolski G.

European Journal of Translational and Clinical Medicine

|

2021

|

vol. 4

|

issue 2

10-17

EN

In this report we present pulmonary vein and posterior box isolation together with the right superior ganglion plexus ablation using the Qdot Micro catheter without fluoroscopy. We describe different possibilities of this new technology for catheter ablation. The main advantages of this catheter to potentially increase ablation safety and effectiveness are discussed. Specifically, the possibility to perform high-density mapping with the lowest available distance between points. Furthermore, the possibility to decrease the risk of collateral tissue damage and to improve atrial linear lesions contiguity, transmurality and durability due to the dominance of resistive heating supported by the feedback temperature control. Finally, the possibility to shorten the procedure and fluoroscopy duration due to the high shortening of application duration to 4 seconds only.

5

Dystrofia mięśniowa typu Emery’ego-Dreifussa – spojrzenie kardiologa

100%

Marchel M., Steckiewicz R., Opolski G.

Aktualności Neurologiczne

|

2006

|

vol. 6

|

issue 1

39-43

EN

Emery-Dreifuss muscular dystrophy (EDMD) is characterized by various degrees of cardiac involvement. It concerns clinically asymptomatic patients, patients with arrhythmia, and patients with heart failure due to systolic dysfunction. Cardiomyopathy due to EDMD may lead to sudden cardiac death. The variations in the clinical picture of cardiomyopathy in the two forms of EDMD with regard to the type of inheritance are still unclear. The following paper discusses the most recent papers concerning cardiac complications in EDMD and possibilities of their prevention and therapy. Various cardiologic complications in context of different laminopathies have been presented. It lays particular emphasis on the comprehensiveness of treatment and the interdisciplinary nature of the issue.

PL

Dystrofia mięśniowa typu Emery’ego-Dreifussa (EDMD) charakteryzuje się m.in. różnego stopnia zajęciem mięśnia sercowego. Pacjenci pozostają nierzadko bezobjawowi mimo istotnego uszkodzenia mięśnia sercowego. Kardiomiopatia towarzysząca EDMD może przebiegać z niegroźnymi nadkomorowymi zaburzeniami rytmu, zaburzeniami przewodnictwa przedsionkowo-komorowego wymagającymi niejednokrotnie implantacji układu stymulującego, różnego stopnia bezobjawową dysfunkcją skurczową. Zajęcie mięśnia sercowego może być przyczyną nagłego zgonu. Pytanie o różnice w obrazie kardiologicznym pacjentów z EDMD rozwijającym się na podłożu dwóch różnych defektów genetycznych o odmiennym typie dziedziczenia wciąż pozostaje otwarte. W pracy uwzględniono najnowsze dane dotyczące powikłań kardiologicznych u pacjentów z EDMD, dyskutowano możliwości prewencji i terapii kardiomiopatii towarzyszącej chorobie, jak również zaprezentowano powikłania kardiologiczne w perspektywie innych laminopatii. Podkreślono znaczenie kompleksowej opieki i interdyscyplinarność zagadnienia.

6

Difference in demand for analgesic and sedative medication according to the type of catheter ablation for atrial fibrillation

88%

Koźluk E., Rzechorzek W., Piątkowska A., Rodkiewicz D., Opolski G.

European Journal of Translational and Clinical Medicine

|

2021

|

vol. 4

|

issue 1

35-42

EN

Background: Our aim was to determine if there is a difference in demand for analgesic and sedative medication according to the type of catheter ablation for atrial fibrillation (AF). Material and methods: We collected data from protocols of 1144pts, who underwent ablation of AF. We excluded 275pts, at most due to electrocardioversion during the procedure. We divided them into 4 groups: cryoballoon ablation group (CB, n = 101), single-point radiofrequency ablation group (RFth-, n = 541), single-point radiofrequency ablation group with thermocool catheter (RFth+, n = 156) and Multielectrode Pulmonary Vein Ablation Catheter group (PVAC, n = 71). We used fentanyl and midazolam for pain control. The dose was adjusted by the operator, accord-ing to patients’ request. Results: The median dose of fentanyl 0.04 mg (0.00-0.08) and midazolam 1.00 mg (0.00-2.00) in CB group was lower than in other groups (p < 0.001). The median dose of fentanyl 0.12 mg (0.08-0.17) was lower in RFth- than in in RFth+ group: 0.15 mg (0.1-0.2) (p < 0.001). The demand for analgesia was higher when PVAC was used, with median dose of fentanyl 0.15 mg (0.1-0.2) (p < 0.0024). Conclusions: The demand for analgesic/sedative medication was lower among patients who underwent CB. Among those who underwent RF ablation it was higher in groups with thermocool and multielectrode catheters.

7

Interindividual variability of atorvastatin treatment influence on the MPO gene expression in patients after acute myocardial infarction

64%

Sygitowicz G., Maciejak A., Piniewska-Juraszek J., Pawlak M., Góra M., Burzyńska B., Dłużniewski M., Opolski G., Sitkiewicz D.

Acta Biochimica Polonica

|

2016

|

vol. 63

|

issue 1

89-95

EN

Myeloperoxidase (MPO) and C-reactive protein (CRP) may play critical roles in generation of oxidative stress and the development of the systemic inflammatory response. The aim of the study was to determine the effect of atorvastatin therapy on the MPO gene expression and its plasma level in relation to lipids level lowering and an anti-inflammatory response in patients after acute myocardial infarction. The research material was represented by 112 samples. Thirty-eight patients with first AMI receiving atorvastatin therapy (40 mg/day) and followed up for one month were involved in the study. The relative MPO gene expression in peripheral blood mononuclear cells (PBMCs) was examined using RT-qPCR in 38 patients before-, 38 patients after-therapy and in 36 patients as the control group. The plasma concentrations of MPO and serum concentrations of biochemical parameters were determined using commercially available diagnostic tests. After one month of atorvastatin therapy, in 60.5% patients a decrease of MPO gene expression, whereas in 39.5% patients an increase, was observed. The plasma MPO levels behaved in the same way as the MPO gene expression. However, the serum lipids and CRP concentrations were significantly lower after one month of atorvastatin therapy in both groups of patients - with decreased and increased MPO gene expression. Atorvastatin exhibited a different effect on MPO gene expression and its plasma level. Short-term atorvastatin therapy resulted in lipid lowering and anti-inflammatory activity in patients after AMI, independently of its effect on MPO gene expression. The molecular mechanisms of this phenomenon are not yet defined and require further research.

8

Periprocedural decrease in tumor necrosis factor alpha is a risk factor for atrial fibrillation recurrence after ablation

52%

Szczerba E., Koźluk E., Januszkiewicz Ł., Lisicka M., Nowak J., Kondracka A., Majstrak J., Rodkiewicz D., Piątkowska A., Kiliszek M., Opolski G.

European Journal of Translational and Clinical Medicine

|

2022

|

vol. 5

|

issue 2

16-23

EN

Background Concentration of tumor necrosis factor alpha (TNF-alpha) might be useful in selecting patients with paroxysmal atrial fibrillation (PAF) who will benefit the most from pulmonary vein isolation. Material and methods We performed prospective cohort study among patients with PAF who had sinus rhythm prior to undergoing either radiofrequency ablation or cryoablation procedure. Blood samples were collected at the start of the procedure and 16-24 h after. TNF-alpha concentrations were measured. Follow-up data was obtained during a structured telephone interview and 24-hour ECG Holter monitoring 12 months after the ablation procedure. Results Thirty seven patients were enrolled. After 12-month follow-up 27 patients maintained sinus rhythm, 8 had recurrence of AF and 2 were lost to follow-up. There was no significant correlation between TNF-alpha concentrations in any of the samples and the recurrence of arrhythmia (for pre-procedural samples: 1.75 pg/ml vs 1.74 pg/ml; p=0.72; for post-procedural samples: 1.49 pg/ml vs 1.79 pg/ml; p=0.16). In patients who had a recurrence of AF, we observed a decrease in the periprocedural TNF-alpha concentration (-0.12 pg/ml vs 0.05 pg/ml; p=0.05). Conclusions Neither pre- nor post-procedural TNF-alpha concentrations are predictive of ablation outcome in patients with PAF. We observed a decrease in the periprocedural TNF-alpha concentration in patients who had AF recurrence.

Refine search results

Irrigated DiamondTemp catheter and return to ablation under temperature control. First Polish experience with DiamondTemp catheter in pulmonary vein isolation

Stanowisko w sprawie stosowania niepegylowanej liposomalnej doksorubicyny u chorych na chłoniaki ze współistniejącymi chorobami sercowo-naczyniowymi

Cardioneuroablation in neurocardiogenic syncope – hype or hope?

High-power and short-duration ablation with the Qdot+ algorithm for pulmonary vein isolation and the right superior ganglion plexus ablation without fluoroscopy

Dystrofia mięśniowa typu Emery’ego-Dreifussa – spojrzenie kardiologa

Difference in demand for analgesic and sedative medication according to the type of catheter ablation for atrial fibrillation

Interindividual variability of atorvastatin treatment influence on the MPO gene expression in patients after acute myocardial infarction

Periprocedural decrease in tumor necrosis factor alpha is a risk factor for atrial fibrillation recurrence after ablation